Gonzalez David Angulo - 01 Apr 2026 Form 4 Insider Report for SCYNEXIS INC (SCYX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SCYX
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 08:01:21 UTC
Prior SEC filing: 02 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert F. Joyce Jr., by Power of Attorney

Key filing fact

Gonzalez David Angulo filed Form 4 for SCYNEXIS INC (SCYX) on 02 Apr 2026.

Key facts

This page summarizes Gonzalez David Angulo's Form 4 filing for SCYNEXIS INC (SCYX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 08:01.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644071 Primary reporting owner

Angulo Gonzalez David

Relationship: Chief Executive Officer, Director
Address: 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY
Signature: /s/ Robert F. Joyce Jr., by Power of Attorney
Signature date: 02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCYX transaction

Common Stock

Purchase

Transaction value
Shares: +108,695
Change %: +8.7%
Price
Shares after: 1,357,126
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCYX transaction Derivative

Warrant to Purchase Common Stock

Purchase

Transaction value
Shares: +108,695
Change %
Price
Shares after: 108,695
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 108,695
Exercise price: $1.20
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92.

Footnote F2

Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer on March 5, 2026.

Footnote F3

The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Issuer's authorized shares of common stock.

Footnote F4

The Common Warrants will expire on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Issuer publicly releases topline data at Week 48 from the Issuer's Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease.